

The GOG Highlight Reel, An Education Series Highlighting Newsworthy Distillations and Emerging Therapies in Gynecologic Clinical Trials

January 23, 2026

San Francisco, CA

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** *(formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations**.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. "Relevant" financial relationships are financial transactions (in any amount) occurring within the **past 24 months** that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An "**ineligible company**" is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

LAST NAME	FIRST NAME	Individual's Role(s) in Activity	Name of Ineligible Company(s)	Nature of Relevant Financial Relationship(s)
Planning Disclosures				
Herzog, MD	Thomas	Planner/ Moderator	Astra Zeneca; Caris; Clovis; Eisai; Epsilon; Genentech; GSK; J&J; Merck; Mersana; Novocure; Seattle Genetics	Scientific Advisory Boards
Monk, MD	Bradley	Planner/ Moderator	Acrivon Adaptimmune ; Agenus; Akeso Bio; Amgen; AstraZeneca; Biohaven; BMS; Corcept; Eisai; Eli Lilly; Genmab; Seagen; Pfizer; Genalux; GOG Foundation; Gradalis; GSK; HengRui; Immunogen; Abbvie; Karyopharm; Iovance; Merck; Mersana; Mural; Alkermes; Myriad; Novartis; Novocure; OncoC4; Panavance; Profound Bio; Regeneron; Roche; Genentech; Sutro; Verastem; Zentalis; Zymeworks	Consultant (Acrivon Adaptimmune ; Agenus; Akeso Bio; Amgen; AstraZeneca; Biohaven; BMS; Corcept; Eisai; Eli Lilly; Genmab; Seagen; Pfizer; Genalux; GOG Foundation; Gradalis; GSK; HengRui; Immunogen; Abbvie; Karyopharm; Iovance; Merck; Mersana; Mural; Alkermes; Myriad; Novartis; Novocure; OncoC4; Panavance; Profound Bio; Regeneron; Roche; Genentech; Sutro; Verastem; Zentalis; Zymeworks) Speaker (AstraZeneca; Eisai; GSK; Immunogen; Abbvie; Merck)
Speaker Disclosures				
Coleman, MD	Robert	Speaker	Mural; AstraZeneca; Pharma&; Eisai; Genentech USA Inc; GSK; Gradalis; Mersana; Novocure; Abbvie; Immunogen, Abbvie; Merck; Novartis; Valero/Valbio; Seagen/Genmab/Pfizer; VBL; Eisai; GOG-Partners; Karyopharm	Consultant (Mural; AstraZeneca; Pharma&; Eisai; Genentech USA Inc; GSK; Gradalis; Mersana; Novocure; Seagen/Genmab/Pfizer) Grant Contract (Genentech USA Inc; Abbvie; Immunogen, Abbvie; Merck; Novartis; Valero/Valbio; Seagen/Genmab/Pfizer; Karyopharm)

FACULTY DISCLOSURE INFORMATION

				Data & Safety Monitoring (VBL; Eisai; GOG-Partners)
Eskander, MD	Ramez	Speaker	AstraZeneca, MSD, Regeneron, PMV Pharmaceuticals, Daiichi Sanyo, GSK, Myriad, Seagen, Abbvie, Pfizer, Novocure, BioNTech, Eisai, Roche, Mersana; Nuvectis Pharma, Merck, Loxo @ Lilly, Genmab/Seagen, Clovis Oncology, Acrivon therapeutics, Zentalis, Eisai, Gilead, Roche	Consultant (AstraZeneca, MSD, Regeneron, PMV Pharmaceuticals, Daiichi Sankyo, GSK, Myriad, Seagen, Abbvie, Pfizer, Novocure, BioNTech, Eisai, Roche, Mersana) Research Funding (Nuvectis Pharma, GSK, Merck, Daiichi Sankyo, Loxo @ Lilly, AstraZeneca, Genmab/Seagen, Clovis Oncology, Acrivon Therapeutics, Zentalis, Eisai, Gilead, Roche)
Grisham, MD	Rachel	Speaker	AstraZeneca; GSK; Incyte; GenMab; Verastem; SpringWorks; Myriad	Consultant
Moore, MD	Kathleen	Speaker	Research To Practice; Great Debates and Updates; Astellas Medivation; Clarity Foundation; IDEology Health; Medscape; OncoLive/MJH Life Sciences; MD Outlook; Curio Science; Plexus; University of Florida; University of Arkansas for Medical Sciences; Congress Channel; BIOPHARM; CEA/CCO; Physician Education Resource (PER); Med Learning Group; Peervue; PeerVoice; CME Outfitters; virtual incision; GOG Partners; NRG Ovarian Committee; Immunogen; AstraZeneca; Merck; Eisai; Verastem/Pharmacyclics; AADI; Caris Life Sciences; Iovance Biotherapeutics; Janssen Oncology; Regeneron; zentalis; Daiichi Sankyo Europe GmbH; BioNTech SE; immunocore; seagen; Takeda Science Foundation; zymeworks; profound bio; ADC Therapeutics; Corcept Therapeutics; Third Arc; Loxo/Lilly; Bristol Meyers Squibb Foundation; Tango Therapeutics; Abbvie; T knife; F Hoffman LaRoche; Tubulis GnbH; Clovis Oncology; Kivu; Genmab/Seagen; Whitehawk; OnCusp Therapeutics; Natera; BeiGene; Karyopharm Therapeutics; Day One Biopharmaceuticals; Debiopharm Group; Foundation Medicine; Novocure; Mersana; GSK/Tesaro; Duality Biologics; Schrodinger; Regeneron; Verastem; Daiichi Sankyo/Lilly; Torl Biotherapeutics; Allerity Therapeutics; IDEAYA Biosciences; Zymeworks; International Gynecologic Cancer Society	Honoraria (Research To Practice; Great Debates and Updates; Astellas Medivation; Clarity Foundation; IDEology Health; Medscape; OncoLive/MJH Life Sciences; MD Outlook; Curio Science; Plexus; University of Florida; University of Arkansas for Medical Sciences; Congress Channel; BIOPHARM; CEA/CCO; Physician Education Resource (PER); Med Learning Group; Peervue; PeerVoice; CME Outfitters; virtual incision) Leadership (GOG Partners; NRG Ovarian Committee Chair) Consulting or Advisory Role (Genentech/Roche; Immunogen; AstraZeneca; Merck; Eisai; Verastem/Pharmacyclics; AADI; Caris Life Sciences; Iovance Biotherapeutics; Janssen Oncology; Regeneron; zentalis; Daiichi Sankyo Europe GmbH; BioNTech SE; immunocore; seagen; Takeda Science Foundation; zymeworks; profound bio; ADC Therapeutics; Corcept Therapeutics; Third Arc; Loxo/Lilly; Bristol Meyers Squibb Foundation; Tango Therapeutics; Abbvie; T knife; F Hoffman LaRoche; Tubulis GnbH; Clovis Oncology; Kivu; Genmab/Seagen; Whitehawk; OnCusp Therapeutics; Natera; BeiGene; Karyopharm Therapeutics; Day One Biopharmaceuticals; Debiopharm Group; Foundation Medicine; Novocure; Mersana; GSK/Tesaro; Duality Biologics; Schrodinger) Research Funding to Institution (Merck; Regeneron; Verastem; AstraZeneca; Immunogen; Daiichi Sankyo/Lilly; Immunocore; Torl Biotherapeutics; Allerity Therapeutics; IDEAYA Biosciences; Zymeworks; Schrodinger) Uncomp Relationships (International Gynecologic Cancer Society) Other Relationship (GOG Partners)
O'Malley, MD	David	Speaker	AbbVie; AdaptImmune; Advaxis; Agenus, Inc; Alkermes; Aravive, Inc.;	Institution Received Funds

FACULTY DISCLOSURE INFORMATION

			Arcus Biosciences, Inc.; Arquer Diagnostics; AstraZeneca; Atossa Therapeutics; BeiGene USA, Inc.; Boston Biomedical; Bristol Myers Squibb; Cardiff Oncology; Celcuity; Clovis Oncology; Corcept Therapeutics; Deciphera Pharma; Duality Bio; Eisai; Elevar; EMD Serono, Inc.; Exelixis; Genentech Inc; Genmab; Genelux; GlaxoSmithKline; GOG Foundation; Hoffmann-La Roche Inc; ImmunoGen, Inc; Imvax; InterVenn; INXMED; Incyte Corporation; IOVANCE Biotherapeutics; Jazz Pharmaceuticals; Karyopharm; Laekna; Leap Therapeutics, Inc.; Ludwig Institute for Ca; Luzsana Biotechnology; Merck & Co; Merck Sharp & Dohme Corp.; Mersana Therapeutics, Inc.; Myriad; NCI; Novartis; NovoCure; NRG Oncology; OncoC4, Inc.; OncoQuest Inc.; Onconova; Pfizer Inc; Precision Therapeutics, Inc.; Prelude Therapeutics; Regeneron Pharmaceuticals, Inc; RTOG; Rubius Therapeutics; ReplImmune; R Pharm; Roche Diagnostics; Seattle Genetics (SeaGen); Sorrento; Sutro Biopharma; SWOG; ; Tarveda Therapeutics; Toray; Trillium; Umoja; Verastem, Inc; VBL Therapeutics; Vincerx Pharma; Xencor; Zentalis	for research (AbbVie; Advaxis; Agenesis, Inc; Alkermes; Aravive, Inc.; Arcus Biosciences, Inc.; AstraZeneca; BeiGene USA, Inc.; Boston; Biomedical; Bristol Myers Squibb; Clovis Oncology; Deciphera Pharma; Eisai; EMD Serono, Inc.; Exelixis; Genentech Inc; Genmab; GlaxoSmithKline; GOG Foundation; Hoffmann-La Roche Inc; ImmunoGen, Inc; Incyte Corporation; IOVANCE Biotherapeutics; Karyopharm; Leap Therapeutics, Inc.; Ludwig Institute for Ca; Merck & Co; Merck Sharp & Dohme Corp.; Mersana Therapeutics, Inc.; NCI; Novartis; NovoCure; NRG Oncology; OncoC4, Inc.; OncoQuest Inc.; Pfizer Inc; Precision Therapeutics, Inc.; Prelude Therapeutics; Regeneron Pharmaceuticals, Inc; RTOG; Rubius Therapeutics; Seattle Genetics (SeaGen); Sutro Biopharma; SWOG; Verastem, Inc) Ad Board/Consultant (AbbVie; AdaptImmune; Agenesis, Inc; Arquer Diagnostics; Arcus Biosciences, Inc.; AstraZeneca; Atossa Therapeutics; Boston Biomedical; Cardiff Oncology; Celcuity; Clovis Oncology; Corcept Therapeutics; Duality Bio; Eisai; Elevar; Exelixis; Genentech Inc; Genelux; GlaxoSmithKline; GOG Foundation; Hoffmann-La Roche Inc; ImmunoGen, Inc; Imvax; InterVenn; INXMED; Jazz Pharmaceuticals; Laekna; Leap Therapeutics, Inc.; Luzsana Biotechnology; Merck & Co; Merck Sharp & Dohme Corp.; Mersana Therapeutics, Inc.; Myriad; Novartis; NovoCure; OncoC4, Inc.; Onconova; Regeneron Pharmaceuticals, Inc; ReplImmune; R Pharm; Roche Diagnostics; Seattle Genetics (SeaGen); Sorrento; Sutro Biopharma; Tarveda Therapeutics; Toray; Trillium; Umoja; Verastem, Inc; VBL Therapeutics; Vincerx Pharma; Xencor; Zentalis
Pothuri, MD, MS	Bhavana	Speaker	AstraZeneca; celsion/Immunon; Clovis Oncology, Inc.; Genentec; Eisai; GlaxoSmithKline; GOG foundation; Imab; Immunogen; Incyte Corporation; Karyopharm Therapeutics; Merck; Mersana; Seagen Inc.; Sutro; Toray Industries	Consultant (AstraZeneca; Eisai; GlaxoSmithKline; GOG foundation; Merck; Mersana; Seagen Inc.; Sutro) Grant/Contract (AstraZeneca; celsion/Immunon; Clovis Oncology, Inc.; Genentec; GlaxoSmithKline; Imab; Immunogen; Incyte Corporation; Karyopharm Therapeutics; Merck; Mersana; Seagen Inc.; Sutro; Toray Industries)
Randall, MD	Leslie	Speaker	AstraZeneca; Genmab; Pfizer; GSK; Eisai; Merck; AbbVie; GOG Foundation	Consultant (AstraZeneca; Genmab; Pfizer; GSK; Eisai; Merck; Abbvie; GOG Foundation)

FACULTY DISCLOSURE INFORMATION

				Research Funding (Merck; AbbVie; GOG Foundation)
Slomovitz, MD	Brian	Speaker	Seagen, Novocure; AstraZeneca; Aadi; Regeneron; Immunocore; Merck; Gilead, Eisai; Incyte	Consultant
Zsiros	Emese	Speaker	Merck and Co; Takeda Oncology; Abbvie; 92Biotech; Iovance; Apellis	Advisor (Merck and Co; Takeda Oncology; Abbvie; 92Biotech; Iovance; Apellis) Clinical Trial Support (Merck and Co)
Engbert	Holley	Staff	Nothing to disclose	
Rush	Heather	Staff	Nothing to disclose	
Shumaker	Kara	Reviewer/Staff	Nothing to disclose	
Small, MPH	Michelle N	Reviewer/Staff	Nothing to disclose	
Alvarez Secord, MD	Angeles	Reviewer/Edu-Chair	AbbVie; Aravive; AstraZeneca; Daiichi Sankyo; Ellipses Pharma; Genmab; GSK; Immunogen; Karyopharm; Merck; Mersana; Myriad; Oncoquest/Canaria Bio; Oncoquest; Roche/Genentech; TORL Biotherapeutics; Zentalis; Foundation Medicine; Gilead; Histosonics; Medtronic; Porject Nana; Up to Date; SGO; FWC; GOG Foundation; Amgen; Johnson & Johnson	Research funds to Institution (AbbVie; Aravive; AstraZeneca; Daiichi Sankyo; Ellipses Pharma; Genmab; GSK; Immunogen; Karyopharm; Merck; Mersana; Myriad; Oncoquest/Canaria Bio; Oncoquest; Roche/Genentech; TORL Biotherapeutics; Zentalis) Honorarium (Merck; GSK) Advisory Board with Honoraria (AbbVie; AstraZeneca; Daiichi Sankyo; Foundation Medicine; GSK; Genmab; Gilead; Histosonics; Medtronic; Merck) Medical Advisory Board (Porject Nana) Steering Committee Uncomp. (Oncoquest; Genmab) Royalties (Up to Date) Board of Directors (SGO; FWC; GOG Foundation) Stock-Divested in June 2024 (Amgen; Johnson & Johnson)
Duska, MD	Linda	Edu-Co-Chair/Reviewer	Merck; Corcept	Honoraria (Merck) Speakers Bureau (Corcept) Research Funding (Merck)
Blank, MD	Stephanie	Reviewer	AstraZeneca; Merck; Zentalis; Acrivon; Seattle Genetics; GSK	Research Funding to Institution
Mutch, MD	David	Reviewer	Nothing to disclose	
Zweizig, MD	Susan	Reviewer	Nothing to disclose	